Prognostic Role of Tumor Budding in Breast Cancer

Overview

Journal World J Exp Med

Publisher Baishideng Publishing Group

Specialty Biomedical Engineering

Date 2018 Sep 14

PMID 30211020

Citations 21

Authors

Ioannis A Voutsadakis

Affiliations

Soon will be listed here.

Abstract

Tumor budding, defined as a small number of cancer cells observed in pathology sections detached from the main tumor mass, is a common phenomenon in cancer. It is suggested that cells in buds are in the process of actively moving away from the primary tumor in the first step of metastasis. Tumor budding has been observed in a variety of carcinomas and is best studied in colorectal cancers where it portends poor prognosis. More recently, tumor budding was found to be of prognostic significance in other cancers including breast cancer. Tumor budding in breast cancer is associated with other adverse pathologic factors, such as larger tumor size and lymphovascular invasion, but may have additional independent prognostic value. In the future, standardization of the quantification criteria for tumor budding may further aid in its adoption as a prognostic marker.

Citing Articles

Tumour budding in invasive ductal breast carcinomas: correlation with clinicopathological prognostic parameters and hormone receptor status.

Francis S, Sharma S Pathol Oncol Res. 2025; 31:1611983.

PMID: 40012857 PMC: 11862687. DOI: 10.3389/pore.2025.1611983.

The Prognostic Significance of Tumor Budding and Cell Nest Size in Laryngeal Squamous Cell Carcinoma.

Anousha K, Shekari M, Mirzaian E, Yousefi T, Beheshti A, Lotfi M Cancer Rep (Hoboken). 2024; 7(11):e70052.

PMID: 39589172 PMC: 11590330. DOI: 10.1002/cnr2.70052.

Epithelial-Mesenchymal Transition Indexes in Triple-Negative Breast Cancer Progression and Metastases.

Kepuladze S, Burkadze G, Kokhreidze I Cureus. 2024; 16(9):e68761.

PMID: 39371729 PMC: 11456157. DOI: 10.7759/cureus.68761.

The relationship between tumor budding and survival of patients with breast cancer: A meta-analysis.

Xu H, Wei D Biomol Biomed. 2024; 24(6):1546-1558.

PMID: 39319896 PMC: 11496871. DOI: 10.17305/bb.2024.11103.

Identification of Tumor Budding-Associated Genes in Breast Cancer through Transcriptomic Profiling and Network Diffusion Analysis.

Janyasupab P, Singhanat K, Warnnissorn M, Thuwajit P, Suratanee A, Plaimas K Biomolecules. 2024; 14(8).

PMID: 39199284 PMC: 11352152. DOI: 10.3390/biom14080896.

References

Petrelli F, Pezzica E, Cabiddu M, Coinu A, Borgonovo K, Ghilardi M . Tumour Budding and Survival in Stage II Colorectal Cancer: a Systematic Review and Pooled Analysis. J Gastrointest Cancer. 2015; 46(3):212-8. DOI: 10.1007/s12029-015-9716-1. View

Ithimakin S, Day K, Malik F, Zen Q, Dawsey S, Bersano-Begey T . HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab. Cancer Res. 2013; 73(5):1635-46. PMC: 3600586. DOI: 10.1158/0008-5472.CAN-12-3349. View

Mu Z, Wang C, Ye Z, Austin L, Civan J, Hyslop T . Prospective assessment of the prognostic value of circulating tumor cells and their clusters in patients with advanced-stage breast cancer. Breast Cancer Res Treat. 2015; 154(3):563-71. DOI: 10.1007/s10549-015-3636-4. View

Dalerba P, Sahoo D, Paik S, Guo X, Yothers G, Song N . CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer. N Engl J Med. 2016; 374(3):211-22. PMC: 4784450. DOI: 10.1056/NEJMoa1506597. View

Kalluri R, Weinberg R . The basics of epithelial-mesenchymal transition. J Clin Invest. 2009; 119(6):1420-8. PMC: 2689101. DOI: 10.1172/JCI39104. View

Brabletz T, Spaderna S, Kolb J, Hlubek F, Faller G, Bruns C . Down-regulation of the homeodomain factor Cdx2 in colorectal cancer by collagen type I: an active role for the tumor environment in malignant tumor progression. Cancer Res. 2004; 64(19):6973-7. DOI: 10.1158/0008-5472.CAN-04-1132. View

Voutsadakis I . The ubiquitin-proteasome system and signal transduction pathways regulating Epithelial Mesenchymal transition of cancer. J Biomed Sci. 2012; 19:67. PMC: 3418218. DOI: 10.1186/1423-0127-19-67. View

Rogers A, Gibbons D, Hanly A, Hyland J, OConnell P, Winter D . Prognostic significance of tumor budding in rectal cancer biopsies before neoadjuvant therapy. Mod Pathol. 2013; 27(1):156-62. DOI: 10.1038/modpathol.2013.124. View

Liang F, Cao W, Wang Y, Li L, Zhang G, Wang Z . The prognostic value of tumor budding in invasive breast cancer. Pathol Res Pract. 2013; 209(5):269-75. DOI: 10.1016/j.prp.2013.01.009. View

10.

Whitworth P, Stork-Sloots L, de Snoo F, Richards P, Rotkis M, Beatty J . Chemosensitivity predicted by BluePrint 80-gene functional subtype and MammaPrint in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST). Ann Surg Oncol. 2014; 21(10):3261-7. PMC: 4161926. DOI: 10.1245/s10434-014-3908-y. View

11.

Karamitopoulou E, Zlobec I, Born D, Kondi-Pafiti A, Lykoudis P, Mellou A . Tumour budding is a strong and independent prognostic factor in pancreatic cancer. Eur J Cancer. 2012; 49(5):1032-9. DOI: 10.1016/j.ejca.2012.10.022. View

12.

Enderle-Ammour K, Bader M, Ahrens T, Franke K, Timme S, Csanadi A . Form follows function: Morphological and immunohistological insights into epithelial-mesenchymal transition characteristics of tumor buds. Tumour Biol. 2017; 39(5):1010428317705501. DOI: 10.1177/1010428317705501. View

13.

Dawson H, Koelzer V, Karamitopoulou E, Economou M, Hammer C, Muller D . The apoptotic and proliferation rate of tumour budding cells in colorectal cancer outlines a heterogeneous population of cells with various impacts on clinical outcome. Histopathology. 2013; 64(4):577-84. DOI: 10.1111/his.12294. View

14.

Voutsadakis I . Ubiquitination and the Ubiquitin-Proteasome System as regulators of transcription and transcription factors in epithelial mesenchymal transition of cancer. Tumour Biol. 2012; 33(4):897-910. DOI: 10.1007/s13277-012-0355-x. View

15.

Voutsadakis I . Epithelial-Mesenchymal Transition (EMT) and Regulation of EMT Factors by Steroid Nuclear Receptors in Breast Cancer: A Review and in Silico Investigation. J Clin Med. 2016; 5(1). PMC: 4730136. DOI: 10.3390/jcm5010011. View

16.

Masood S . Neoadjuvant chemotherapy in breast cancers. Womens Health (Lond). 2016; 12(5):480-491. PMC: 5373271. DOI: 10.1177/1745505716677139. View

17.

Gavert N, Ben-Shmuel A, Lemmon V, Brabletz T, Ben-Zeev A . Nuclear factor-kappaB signaling and ezrin are essential for L1-mediated metastasis of colon cancer cells. J Cell Sci. 2010; 123(Pt 12):2135-43. PMC: 4481617. DOI: 10.1242/jcs.069542. View

18.

Kadota K, Yeh Y, Villena-Vargas J, Cherkassky L, Drill E, Sima C . Tumor Budding Correlates With the Protumor Immune Microenvironment and Is an Independent Prognostic Factor for Recurrence of Stage I Lung Adenocarcinoma. Chest. 2015; 148(3):711-721. PMC: 4556124. DOI: 10.1378/chest.14-3005. View

19.

Li X, Wei B, Sonmez C, Li Z, Peng L . High tumor budding count is associated with adverse clinicopathologic features and poor prognosis in breast carcinoma. Hum Pathol. 2017; 66:222-229. DOI: 10.1016/j.humpath.2017.06.008. View

20.

Mani S, Guo W, Liao M, Eaton E, Ayyanan A, Zhou A . The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008; 133(4):704-15. PMC: 2728032. DOI: 10.1016/j.cell.2008.03.027. View